This webinar featured Jean-Michel Molina of the French research agency ANRS and Sheena McCormack of the UK Medical Research Council discussing the data from the IPERGAY and PROUD studies, respectively. Both trials evaluated oral TDF/FTC (brand name Truvada) as PrEP in gay men and other men who have sex with men, and both reported high levels of protection against HIV acquisition. PROUD prescribed a daily pill regimen; IPERGAY asked trial participants to follow an “event driven” regimen that involved a sequence of doses before and after sex. IPERGAY participants took an average of four doses per week—comparable to the estimated protective dose required in trials of daily oral PrEP.
Prepare for the webinar with these talks from CROI and excerpts from AVAC Report 2014/15:
- CROI Webcast: On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
- CROI Webcast: Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study
- CROI Plenary Webcast: PrEP for HIV Prevention: What We Know and What We Still Need to Know for Implementation, Raphael Landovitz, University of California Los Angeles
- Excerpt from AVAC Report on PrEP